Patents by Inventor Nicholas J. Donato
Nicholas J. Donato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9868736Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I).Type: GrantFiled: October 10, 2014Date of Patent: January 16, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Nicholas J. Donato, Moshe Talpaz, Luke Peterson, Matthew Young, Hollis D. Showalter, Christiane Wobus, Mary Xuan Dziem O'Riordan, Monika Ermann
-
Publication number: 20160237082Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I)Type: ApplicationFiled: October 10, 2014Publication date: August 18, 2016Inventors: Nicholas J. Donato, Moshe Talpaz, Luke Peterson, Matthew Young, Hollis D. Showalter, Christiane Wobus, Mary Xuan Dziem O'Riordan, Monika Ermann
-
Publication number: 20140357673Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.Type: ApplicationFiled: July 31, 2014Publication date: December 4, 2014Inventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey William Perry, Roderick Joseph Sorenson, Mary Xuan Dziem O'Riordan, Yafei Jin
-
Patent number: 8809377Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g.Type: GrantFiled: September 23, 2011Date of Patent: August 19, 2014Assignee: The Regents of the University of MichiganInventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey W. Perry, Roderick J. Sorenson, Mary X. O'Riordan, Yafei Jin
-
Publication number: 20130012519Abstract: A method of identifying cancer or an associated disorder comprising identifying and quantifying STAT3 occurring in a biological sample taken from a subject after administering a SFK inhibitor to said subject.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicants: BRISTOL-MYERS SQUIBB COMPANY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Faye M. Johnson, Nicholas J. Donato, Francis Y. Lee
-
Patent number: 8268837Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.Type: GrantFiled: November 22, 2005Date of Patent: September 18, 2012Assignees: Novartis AG, GSF, University of Texas SystemInventors: Nicholas J Donato, Doriano Fabbro, Paul W Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Publication number: 20120077806Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey W. Perry, Roderick J. Sorenson, Mary X. O'Riordan, Yafei Jin
-
Patent number: 8119649Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.Type: GrantFiled: May 14, 2009Date of Patent: February 21, 2012Assignees: Novartis AG, GSF-International Research Institute for Environment and Health, Board of Regents, The University of Texas systemInventors: Nicholas J Donato, Doriano Fabbro, Paul W Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Publication number: 20100292229Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.Type: ApplicationFiled: July 2, 2007Publication date: November 18, 2010Applicant: The Board of Regents of the University of Texas SystemInventors: Nicholas J Donato, David Maxwell, Moshe Talpaz, William Bornmann, Zhenghong PENG, Ashutosh Pal, Dongmei Han, Shimei Wang, Geoffrey Bartholomeusz, Vaibhav Kapuria
-
Publication number: 20100173426Abstract: A method of identifying cancer or an associated disorder comprising identifying and quantifying STAT3 occurring in a biological sample taken from a subject after administering a SFK inhibitor to said subject.Type: ApplicationFiled: December 18, 2007Publication date: July 8, 2010Inventors: Faye M. Johnson, Nicholas J. Donato, Francis Y. Lee
-
Publication number: 20090227608Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.Type: ApplicationFiled: May 14, 2009Publication date: September 10, 2009Inventors: Nicholas J. Donato, Doriano Fabbro, Paul William Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Patent number: 6923993Abstract: The present invention is directed to a process of isolating an extract from a Euphorbia obesa (EO) plant by: preparing a sample of said plant comprising removal of the latex material; dissolving said sample with first solvent to form a solution; separating said solution into a liquid and a pulp fraction; and purifying said pulp fraction. The isolated EO extract induces apoptosis and inhibits growth of a cancerous cell. Thus, the present invention is also directed to a method for inducing apoptosis and growth inhibition of a cancerous cell by contacting the cell with an effective amount of the EO extract by the process of the invention. Preferably, the extract is administered both to the tumor directly and intravenously. The preferred lines of cancerous cells are melanoma, non-small cell lung cancer, prostate cancer, breast carcinoma, ovarian cancer, lymphoma and leukemia cells.Type: GrantFiled: December 12, 2001Date of Patent: August 2, 2005Inventors: Nicholas D. Donato, Nicholas J. Donato, David C. Sample, Margot Perez, John S. McMurray, Robert A Newman
-
Publication number: 20040248906Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tee kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}4-(3-pyridyl)-2-pyrimidine-amine.Type: ApplicationFiled: July 29, 2004Publication date: December 9, 2004Inventors: Nicholas J Donato, Doriano Fabbro, Paul William Manley, Jurgen Mestan, Markus Warmuth, Michael Halleck, Moshe Talpaz, Ji Wu
-
Publication number: 20030118677Abstract: The present invention is directed to a process of isolating an extract from a Euphorbaciae obesa (EO) plant by: preparing a sample of said plant comprising removal of the latex material; dissolving said sample with first solvent to form a solution; seperating said solution into a liquid and a pulp fraction; and purifying said pulp fraction. The isolated EO extract induces apoptosis and inhibits growth of a cancerous cell. Thus, the present invention is also directed to a method for inducing apoptosis and growth inhibition of a cancerous cell by contacting the cell with an effective amount of the EO extract by the process of the invention. Preferably, the extract is administered both to the tumor directly and intravenously. The preferred lines of cancerous cells are melanoma, non-small cell lung cancer, prostate cancer, breast carcinoma, ovarian cancer, lymphoma and leukemia cells.Type: ApplicationFiled: December 12, 2001Publication date: June 26, 2003Applicant: Credere CorporationInventors: Nicholas D. Donato, Nicholas J. Donato, David C. Sample, Margot Perez, John S. McMurray, Robert A. Newman
-
Patent number: 6306626Abstract: The present invention provides an anti-IgM antibody conjugate comprising: a monoclonal antibody which binds selectively to IgM antibody, does not bind to IgG1 or IgG2 antibody, and has a G isotype; and a cytotoxic moiety conjugated to said monoclonal antibody. The present invention also provides a method for collecting hybridoma producing IgG isotype monoclonal antibodies comprising: treating a hybrid cell population with a monoclonal antibody which has a G isotype and binds selectively to IgM antibody but does not bind to IgG1 or IgG2 antibody; subjecting said resulting immuncomplexed cells to sorting; and collecting the cells which have not complexed with said antibodies.Type: GrantFiled: February 7, 1994Date of Patent: October 23, 2001Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Nicholas J. Donato
-
Patent number: 6214974Abstract: The present invention provides a non-viral vector, comprising a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. Also, provided is a method of introducing genetic material inside a specific cell comprising the administration of the non-viral vector to a human, wherein said non-viral vector comprises a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. In addition, there is provided a method of delivering a cytotoxic moiety to a cell comprising the administration of the non-viral vector to a human.Type: GrantFiled: March 27, 1995Date of Patent: April 10, 2001Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Nicholas J. Donato